Koh-ichi Sugimoto*, Shuichi Tsuruoka and Akio Fujimura
Department of Clinical Pharmacology, Jichi Medical School, 3311-1 Minamikawachi-machi,
Kawachi-gun, Tochigi 329-0498, Japan
*Corresponding author. FAX: +81-285-44-7562
E-mail: ksugi@jichi.ac.jp
Abstract: We examined whether nitro-L-arginine-methyl
ester (L-NAME)
causes a sustained elevation in plasma fibrinogen concentration in rats.
Oral dosing of L-NAME (100 mg/kg per day) for 7 days
significantly raised plasma fibrinogen concentration in rats. The increase
in plasma fibrinogen, however, returned to control levels by the treatment
for more than 7 days, in spite of progressive hypertension. Candesartan
failed to reverse the transient hyperfibrinogenemia, indicating that the
rise in plasma fibrinogen may occur through the mechanisms other than angiotensin
II receptor activation. These data suggest that a prolongedL-NAME
treatment does not cause chronic hyperfibrinogenemia in rats.
Keywords: Nitro-L-arginine-methyl ester (L-NAME),
L-NAME-induced hypertension, Fibrinogen
Copyright The Japanese Pharmacological Society
[Back to TOC]